EA200300215A1 - Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой - Google Patents

Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой

Info

Publication number
EA200300215A1
EA200300215A1 EA200300215A EA200300215A EA200300215A1 EA 200300215 A1 EA200300215 A1 EA 200300215A1 EA 200300215 A EA200300215 A EA 200300215A EA 200300215 A EA200300215 A EA 200300215A EA 200300215 A1 EA200300215 A1 EA 200300215A1
Authority
EA
Eurasian Patent Office
Prior art keywords
host cell
vaccination against
economic
cells
virus
Prior art date
Application number
EA200300215A
Other languages
English (en)
Other versions
EA010721B1 (ru
Inventor
Франк Фелер
Клаус Остерридер
Original Assignee
Ломанн Энимал Хелт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ломанн Энимал Хелт Гмбх Унд Ко. Кг filed Critical Ломанн Энимал Хелт Гмбх Унд Ко. Кг
Publication of EA200300215A1 publication Critical patent/EA200300215A1/ru
Publication of EA010721B1 publication Critical patent/EA010721B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области так называемых ассоциированных с хозяйской клеткой вирусов герпеса, подобных вирусу болезни Марека птиц (MDV) и вирусу ветряной оспы человека (VZV), и вакцинации против заболевания, вызываемого указанными вирусами. Изобретение относится к вакцине, направленной против инфекции, вызываемой вирусом герпеса, который является, по существу, ассоциированным с хозяйской клеткой, включающей рекомбинантный вирусный геном, полученный из указанного вируса герпеса, причем указанный геном позволяет осуществлять рекомбинацию, по существу, в отсутствие указанной хозяйской клетки.Отчет о международном поиске был опубликован 2002.04.11.
EA200300215A 2000-08-03 2001-08-01 Вакцина против инфекции, вызванной вирусом герпеса, ассоциированным, по существу, с хозяйской клеткой EA010721B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202757A EP1178111A1 (en) 2000-08-03 2000-08-03 Vaccination against host cell-associated herpesviruses
PCT/EP2001/008893 WO2002012288A2 (en) 2000-08-03 2001-08-01 Vaccination against host cell-associated herpesviruses

Publications (2)

Publication Number Publication Date
EA200300215A1 true EA200300215A1 (ru) 2003-08-28
EA010721B1 EA010721B1 (ru) 2008-10-30

Family

ID=8171884

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300215A EA010721B1 (ru) 2000-08-03 2001-08-01 Вакцина против инфекции, вызванной вирусом герпеса, ассоциированным, по существу, с хозяйской клеткой

Country Status (24)

Country Link
US (1) US9073979B2 (ru)
EP (2) EP1178111A1 (ru)
JP (1) JP4313036B2 (ru)
KR (1) KR100633180B1 (ru)
CN (2) CN102151333A (ru)
AT (1) ATE412055T1 (ru)
AU (2) AU2001291716B2 (ru)
BR (1) BRPI0112989B1 (ru)
CA (1) CA2417923C (ru)
CZ (1) CZ303904B6 (ru)
DE (1) DE60136278D1 (ru)
EA (1) EA010721B1 (ru)
ES (1) ES2315306T3 (ru)
HR (1) HRP20030147B1 (ru)
HU (1) HU228262B1 (ru)
IL (2) IL154250A0 (ru)
MX (1) MXPA03001027A (ru)
NO (1) NO332621B1 (ru)
NZ (1) NZ524066A (ru)
PL (1) PL207958B1 (ru)
PT (1) PT1307565E (ru)
UA (1) UA84667C2 (ru)
WO (1) WO2002012288A2 (ru)
ZA (1) ZA200300842B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
WO2005085445A1 (ja) * 2004-03-05 2005-09-15 The Research Foundation For Microbial Diseases Of Osaka University 組換え水痘帯状疱疹ウイルス
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
US20080226677A1 (en) * 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US8809047B2 (en) 2009-12-21 2014-08-19 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
US9782474B2 (en) * 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
ES2700243T3 (es) * 2011-10-21 2019-02-14 Intervet Int Bv Construcciones del virus de la enfermedad de Marek recombinantes no patógenas que codifican antígenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad de Newcastle
EP2782597B1 (en) * 2011-11-23 2022-04-13 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN105597095A (zh) * 2015-12-30 2016-05-25 暨南大学 一种应用微载体培养Vero细胞制备基因缺失减毒疫苗的方法
CN105561303B (zh) * 2015-12-30 2019-04-05 暨南大学 单纯疱疹病毒i型ul5基因缺失的dna疫苗的制备方法
CN105641692A (zh) * 2015-12-30 2016-06-08 暨南大学 单纯疱疹病毒ⅰ型基因重组减毒活疫苗及其制备方法
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
US11174322B2 (en) * 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
BR112020012162A2 (pt) * 2017-12-20 2020-11-24 Intervet International B.V. diluente aprimorado para vacina contra alfa-herpesvírus associado à célula
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) * 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
GB8821441D0 (en) 1988-09-13 1988-10-12 Animal Health Inst Viral vectors
EP0486106A3 (en) 1990-11-16 1992-12-23 Akzo N.V. Marek's disease virus vaccine
AU657144B2 (en) * 1991-07-09 1995-03-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant Marek's disease virus, process for preparing the same and vaccine containing the same
JP3675569B2 (ja) 1995-04-28 2005-07-27 日本ゼオン株式会社 組み換えウイルス及びそれよりなるワクチン
KR19990028766A (ko) 1995-07-07 1999-04-15 나카노 가쓰히꼬 마렉 질환 바이러스 유전자 및 마렉 질환 예방용 백신에서그의 용도
US6306387B1 (en) * 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
AUPP684998A0 (en) * 1998-10-30 1998-11-26 Murdoch Institute for Research into Birth Defects Limited, The A method of recombination and agents useful for same
EP1038952A3 (en) 1998-12-09 2001-06-27 Pfizer Products Inc. Processes for preparation of Marek's Disease Virus using continuous avian cell lines
US6410222B1 (en) * 1998-12-14 2002-06-25 Juridical Foundation The Chemosero-Therapeutic Research Institute In ovo vaccination of marek's disease type I virus
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses

Also Published As

Publication number Publication date
ZA200300842B (en) 2004-04-30
EP1307565A2 (en) 2003-05-07
HUP0302664A2 (hu) 2003-11-28
AU2001291716B8 (en) 2002-02-18
MXPA03001027A (es) 2004-02-26
IL154250A (en) 2013-07-31
KR100633180B1 (ko) 2006-10-11
HUP0302664A3 (en) 2004-10-28
ES2315306T3 (es) 2009-04-01
NO20030524L (no) 2003-04-03
DE60136278D1 (de) 2008-12-04
ATE412055T1 (de) 2008-11-15
HU228262B1 (en) 2013-02-28
NO332621B1 (no) 2012-11-19
AU9171601A (en) 2002-02-18
US9073979B2 (en) 2015-07-07
EP1178111A1 (en) 2002-02-06
BRPI0112989B1 (pt) 2015-09-08
HRP20030147B1 (en) 2011-10-31
IL154250A0 (en) 2003-09-17
EA010721B1 (ru) 2008-10-30
HRP20030147A2 (en) 2005-04-30
NO20030524D0 (no) 2003-02-03
PL207958B1 (pl) 2011-02-28
WO2002012288A2 (en) 2002-02-14
CN102151333A (zh) 2011-08-17
CA2417923C (en) 2010-06-29
JP4313036B2 (ja) 2009-08-12
PT1307565E (pt) 2009-01-28
EP1307565B1 (en) 2008-10-22
CN1503843A (zh) 2004-06-09
CA2417923A1 (en) 2002-02-14
JP2004505993A (ja) 2004-02-26
CZ2003324A3 (cs) 2003-06-18
BR0112989A (pt) 2003-09-09
NZ524066A (en) 2004-11-26
KR20030036657A (ko) 2003-05-09
CZ303904B6 (cs) 2013-06-19
US20030165537A1 (en) 2003-09-04
UA84667C2 (ru) 2008-11-25
AU2001291716B2 (en) 2007-06-07
PL365190A1 (en) 2004-12-27
WO2002012288A3 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
EA200300215A1 (ru) Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой
Rapp Plaque differentiation and replication of virulent and attenuated strains of measles virus
EP1298139A3 (en) Avian herpes virus-based recombinant infectious bursal disease vaccine
CN110643632B (zh) 一种基于甲病毒复制子载体的狂犬病毒感染性克隆及制备方法和应用
EP0261940A3 (en) Pseudorabies vaccines and dna vectors for recombination with pox viruses
RU2002100209A (ru) Gm-csf лошади
DK1002055T3 (da) Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning
He et al. Genomic analysis of a Chinese MDV strain derived from vaccine strain CVI988 through recombination
EA200100720A1 (ru) Вирусная вакцина на основе делеционного вируса герпеса крупного рогатого скота типа 1 (bhv-1)
ES2699828T3 (es) Vacuna contra el herpesvirus bovino
Swenson et al. Infectious feline herpesvirus detected in distant bone and tendon following mucosal inoculation of specific pathogen-free cats
CN102140441B (zh) 基于减毒痘苗病毒天坛株为载体的禽流感疫苗
Aricò et al. MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68
CN112481222B (zh) 一种条件复制型重组单纯疱疹病毒、疫苗及其应用
Mahalingam et al. Simian varicella virus
CA2562136A1 (en) Novel infectious bursal disease virus and vaccine containing said virus
Yong-Ke et al. Construction and characterization of a recombinant Fowlpox virus expressing chicken type II interferon
種子野章 et al. Immunological properties of the cell-associated live infectious laryngotracheitis virus.
Reddy et al. Novel insights in the pathogenesis of infectious laryngotracheitis and bronchitis viruses in chickens
Trist et al. Comparison of the genomic short regions of a vaccine strain (SA-2) and a virulent strain (CSW-1) of infectious laryngotracheitis virus (gallid herpesvirus 1)
WO2005009372A3 (en) Marek’s disease virus vaccine
Spaan Background Paper Progress Towards a Coronavirus Recombinant DNA Vaccine
Sinangil et al. Infection of human epithelial cells by Epstein-Barr Virus (EBV): II. Biochemical characterization of EBV-determined proteins synthesized in epithelial cells
Nafie et al. STUDIES ON RINDERPEST LIKE DISEASES AND THEIR COUSES
RU94042470A (ru) Поливалентная вакцина для профилактики болезни марека и способ ее изготовления

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY MD

MK4A Patent expired

Designated state(s): KZ RU